This patent filing shows that Brilacidin will not be parceled out per indication throughout the GI tract but one BP will be given the entire platform. That is the meaning of the term "mantilla" used in the patent filing (a scarf type covering encompassing the entire conditions of the GI tract). They are saying that Brilacidin/ Brilacidin salt in conjunction with an antibiotic will be used for ALL conditions of the GI tract starting at the mouth (Oral Mucocitis) and extending all the way through to Ulcerative Proctitis at the rectum/anus. It will include ALL other IBD conditions in the parts of the GI tract between these two endpoints.
Thus, one would have to give the entire GI platform to one BP so that you do not have a nightmare of trying to keep one licensee from bleeding into another's area IMO.
I believe we get word now on a PII trial for UC pretty darn soon and when those positive results come in we see a MASSIVE bidding war for the GI tract platform for Brilacidin. I expect this to be in the multi billion range at the least.
Leo sees the big picture value of Brilacidin and wants to start pushing it hard on a number of fronts.
By the end of 2021 could also see a major PII trial started for pulmonary indications to include COPD/Bronchitis/Asthma.
We are not golden, we are platinum or whatever metal is more precious than gold.
This patent filing is monumental for long term holders IMO and Dr. Bones should be hailed for posting the finding of the year. Thank you good Dr. for this post.
We had the article yesterday detailing the pulmonary Doctor talking about the other drug that is doing so well in tests (the one that earned the developer the Nobel Prize for Medicine in 2015) and how he described it as a miracle drug. I firmly believe that Brilacidin will be talked about in this same degree of disbelief at how wonderful it is within a matter of a few months.
News 
Market Data 
Discover 
AI
